Chronic Social Defeat Stress (CSDS) Model Development Service
Are you currently facing challenges in developing accurate animal models that reflect the complexities of human psychiatric disorders? Our chronic social defeat stress (CSDS) model development service helps you accelerate drug discovery by providing a validated, comprehensive, and scalable platform for preclinical research. We achieve this through our expert protocol design and detailed behavioral phenotyping, ensuring your drug candidates are tested on a highly translatable model.
The CSDS model development service is a powerful tool for advancing drug discovery in the field of neuropsychiatry. Rooted in a highly-regarded animal paradigm, the CSDS model induces a persistent, depression-like phenotype in rodents, closely mimicking the psychological and physiological impacts of prolonged social stress in humans. The model's ability to segregate subjects into susceptible and resilient phenotypes provides a unique opportunity to study the neurobiological underpinnings of vulnerability and resilience to stress.
How CSDS Model Development Service Can Assist Your Project
At Creative Biolabs, our CSDS model development service is designed to deliver a robust and reliable platform for your preclinical studies. We provide more than just a model; we deliver a complete solution from animal preparation to final data analysis, enabling you to gain actionable insights into your drug candidates' efficacy. Our expertise ensures that you receive the highest quality data, allowing you to confidently progress your research.
Discover How We Can Help - Request a Consultation.
Workflow
Our workflow is a comprehensive, multi-stage process designed for clarity and scientific rigor, ensuring seamless integration with your research pipeline.
| Required Starting Materials | To initiate a CSDS project, clients typically provide a detailed project plan outlining their specific research goals, the compound or therapeutic agent to be tested, and any custom dosing or administration requirements. |
| Final Deliverables | Upon project completion, you will receive a comprehensive final report, which includes raw behavioral data files, detailed statistical analyses, and a summary of key findings and conclusions. |
| Estimated Timeframe | The typical timeframe for a standard CSDS study, including all behavioral assessments, ranges from 4 to 6 weeks, though this can vary depending on the complexity of the drug administration schedule and the number of compounds being tested. |
Why Choose Us?
Choosing CBL for your CSDS model development service gives you access to an unparalleled combination of expertise, validated methodologies, and a commitment to scientific excellence. Our approach ensures that your research benefits from the highest standards of reliability and translatability.
Experience the Advantage - Get a Quote Today.
Customer Reviews
"Using CBL's CSDS model development service in our research has significantly improved the reproducibility of our stress-induced depression studies." — Dr. Je Tr, Research Director
"The inclusion of a female CSDS model has been a game-changer for our work. The data from CBL's service has been consistent, allowing us to confidently explore sex-specific therapeutic targets." — Ma Jn, Principal Investigator
"CBL's comprehensive final report and detailed behavioral analysis saved us countless hours of in-house work and provided the critical data we needed to move forward with our lead candidate." — Dr. Sh Bn, Senior Scientist
Chronic Social Defeat Stress (CSDS) Model
The CSDS model is a robust and ethologically valid animal paradigm that induces a persistent, depression-like phenotype in mice through repeated social subordination. Unlike models that rely on non-specific physical or pharmacological stressors, CSDS simulates a naturalistic social environment where a smaller "intruder" mouse is subjected to brief, daily aggressive encounters with a larger, dominant "aggressor" mouse. Following the confrontation, the mice are housed in the same cage, separated by a perforated divider, ensuring prolonged visual, auditory, and olfactory exposure that perpetuates a state of heightened psychological stress.
This approach provides exceptional translational value due to its high face, construct, and predictive validity:
| Validity | Description |
| Face Validity | The induced behavioral and physiological deficits—including anhedonia, heightened anxiety, social-avoidance behavior, reduced activity in an open field, and impaired performance in long-term memory tests—closely mimic the core symptoms of Major Depressive Disorder and PTSD in humans. |
| Construct Validity | The model is underpinned by key neurobiological changes observed in human stress-related disorders, such as alterations in the mesolimbic dopamine system (specifically the VTA-NAc circuit), dysregulation of the HPA axis, and inflammation-related signaling. |
| Predictive Validity | The CSDS-induced phenotypes are consistently reversed by chronic administration of clinically effective antidepressants. The model's flexibility allows for the evaluation of both chronic and acute antidepressant treatments, as well as client-specified dosing programs, providing unparalleled predictive value for your drug candidates. |
Related Services
Our expertise in the CSDS model is part of a broader suite of services designed to accelerate your neuroscience research. To achieve your project goals, you may also be interested in:
- Target Identification & Validation
- Compound Screening & Profiling
- Pharmacokinetic/Pharmacodynamic (PK/PD) Studies
- Neuroinflammation Research Models
FAQs
Q Can your CSDS model be used to test acute treatments?
Q How can I be sure the model is right for my specific drug candidate?
We are ready to provide detailed information, answer your questions, and discuss your specific project needs.
Contact Our Team for More Information and to Discuss Your Project.
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- iNeuMab™ Mouse Anti-LRP1 Monoclonal Antibody (CBP3363) (Cat#: NAB-0720-Z6479)
- iNeu™ Human Oligodendrocyte Progenitor Cells (OPCs) (Cat#: NCL-2103-P49)
- Human Astrocytes (Cat#: NCC20-9PZ01)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- Human Retinal Epithelial Cell ARPE-19 (Cat#: NCL2110P069)
- Mouse Microglia from C57BL/6 (Cat#: NCL-21P6-082)
- Rat Microglia Cell Line HAPI, Immortalized (Cat#: NCL2110P015)
- Human Astrocytes, Immortalized (Cat#: NCL-2105-P182-AM)
- iNeu™ Human Motor Neurons (Cat#: NCL-2103-P71)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
